The Eye Center of Texas is among the first in the U.S. to offer Epioxa, a newly FDA-approved epithelium-on corneal cross-linking therapy for keratoconus. This innovative treatment aims to enhance patient comfort and recovery while effectively managing keratoconus progression.
Background
Keratoconus is a progressive eye condition that typically begins in adolescence, leading to significant visual impairment. Traditional treatments, such as glasses and contact lenses, may not suffice as the disease advances, necessitating more effective interventions. Corneal cross-linking has emerged as a critical procedure to halt disease progression, with Epioxa representing a significant advancement in this therapeutic approach.
Data Highlights
No numerical data provided in the source material.
Key Findings
Epioxa preserves the corneal epithelium, potentially reducing discomfort and recovery time.
Clinical trials indicate improved corneal stability, particularly in patients aged 13 to 28.
Up to 20% of keratoconus patients may require corneal transplantation without intervention.
The FDA approved Epioxa on October 20, 2025, marking it as the first epithelium-on cross-linking therapy for keratoconus.
The treatment is contraindicated in patients with corneal thickness <325 µm.
Clinical Implications
Epioxa offers a less invasive option for managing keratoconus, which may lead to improved patient outcomes and satisfaction. Clinicians should consider this therapy for eligible patients to enhance treatment efficacy and comfort.
Conclusion
The introduction of Epioxa signifies a pivotal advancement in keratoconus management, emphasizing the importance of patient-centered approaches in ophthalmic care.
